関連する実験動画
Updated: Feb 24, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
1.2K
副甲状腺ホルモンに関連するタンパク質は,イディオパシー性肺線維症の治療標的である
Xue-Quan Fang1,2,3, Suha Lim4,5,6, Yoon-Mi Lee1,3
1Department of Medicinal Biosciences, College of Biomedical and Health Science, Konkuk University, Chungju, Republic of Korea.
Signal transduction and targeted therapy
|February 22, 2026
まとめ
副甲状腺ホルモンのようなホルモン (PTHLH) とそのペプチドであるPTHrP1-34は,支氣管の上皮細胞によって分泌され,線維芽細胞を活性化することによって,異症性肺線維症 (IPF) の進行を促します. この経路をターゲットにすることは,IPFの潜在的な治療戦略を提供します.
科学分野:
- 肺内医学 肺内医学 肺内医学
- 細胞生物学 細胞生物学
- 分子生物学は分子生物学である.
背景:
- Idiopathic pulmonary fibrosis (IPF) の病原性には,パラクリン信号伝達を通じて肺細胞間のクロストークが含まれています.
- 線維芽細胞の活性化とIPFにおける,支氣管上皮質細胞からの溶解性媒介体の役割は,十分に研究されていない.
研究 の 目的:
- 線維芽細胞の活性化と肺線維症の促進における,支氣管上皮質細胞由来媒介体の役割を調査する.
- IPFの新たな治療標的を特定する.
主な方法:
- 人とマウスの肺組織からの大量および単細胞RNA配列のデータの再分析.
- 甲状腺ホルモン関連タンパク質 (PTHrP) とそのペプチド PTHrP1-34のレベルを測定する.
- 細胞ベースのインビトロアッセイとインビボ動物モデル (ブレオミシン誘発性肺線維症).
- PTHrP1-34/副甲状腺ホルモン1受容体軸を標的とした中和抗体,ペプチド,遺伝子サイレンシングを用いた臨床前評価.
主要な成果:
- 副甲状腺ホルモンのようなホルモン (PTHLH) とPTHrPは,IPF肺組織と支氣管上皮質において著しく上調された.
- PTHrP1-34は,線維性肺に上昇し,線維芽細胞を活性化し,細胞外マトリックス生成を促進しました.
- PTHrP1-34/副甲状腺ホルモン1受容体軸をターゲットにすることで,マウスモデルでの肺線維症に対する減弱効果が実証されました.
結論:
- bronchial epithelial cellsから派生したPTHrP1-34は,IPFの病原化に寄与する.
- PTHrP1-34 / 副甲状腺ホルモン1受容体軸は,IPF治療のための有望な治療目標です.
関連する概念動画
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
591
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
591
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
545
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
545
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
506
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
506
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
01:30Pulmonary Hypertension: Classification and Pathogenesis
703
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
703
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
649
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
649